172 related articles for article (PubMed ID: 34710981)
1. Overexpression of c-Met is Associated with Poor Prognosis in Glioblastoma Multiforme: A Systematic Review and Meta-Analyses.
Anton J; Sudibio S; Handoko H; Permata TBM; Kodrat H; Nuryadi E; Sofyan H; Susanto E; Mulyadi R; Aman RA; Gondhowiardjo S
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3075-3080. PubMed ID: 34710981
[TBL] [Abstract][Full Text] [Related]
2. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme.
Liu W; Fu Y; Xu S; Ding F; Zhao G; Zhang K; Du C; Pang B; Pang Q
J Clin Neurosci; 2011 Jan; 18(1):119-21. PubMed ID: 20832323
[TBL] [Abstract][Full Text] [Related]
3. The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme.
Olmez OF; Cubukcu E; Evrensel T; Kurt M; Avci N; Tolunay S; Bekar A; Deligonul A; Hartavi M; Alkis N; Manavoglu O
Clin Transl Oncol; 2014 Feb; 16(2):173-7. PubMed ID: 23740136
[TBL] [Abstract][Full Text] [Related]
4. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-analysis.
Chen Y; Hu F; Zhou Y; Chen W; Shao H; Zhang Y
Arch Med Res; 2013 May; 44(4):281-90. PubMed ID: 23608672
[TBL] [Abstract][Full Text] [Related]
5. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
Chaddad A; Sabri S; Niazi T; Abdulkarim B
Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
[TBL] [Abstract][Full Text] [Related]
6. Comparison of neutrophil to lymphocyte ratio and prognostic nutritional index with other clinical and molecular biomarkers for prediction of glioblastoma multiforme outcome.
Garrett C; Becker TM; Lynch D; Po J; Xuan W; Scott KF; de Souza P
PLoS One; 2021; 16(6):e0252614. PubMed ID: 34138894
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis.
Zhou J; Xu T; Qin R; Yan Y; Chen C; Chen Y; Yu H; Xia C; Lu Y; Ding X; Wang Y; Cai X; Chen J
J Neurooncol; 2012 Nov; 110(2):195-203. PubMed ID: 22972189
[TBL] [Abstract][Full Text] [Related]
8. CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme.
Zhao H; Zhou X; Yuan G; Hou Z; Sun H; Zhai N; Huang B; Li X
Clin Transl Oncol; 2021 Mar; 23(3):565-571. PubMed ID: 32661826
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of resection extent for patients with glioblastoma multiforme: a meta-analysis.
Li XZ; Li YB; Cao Y; Li PL; Liang B; Sun JD; Feng ES
J Neurosurg Sci; 2017 Dec; 61(6):631-639. PubMed ID: 26824196
[TBL] [Abstract][Full Text] [Related]
11. Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis.
Mistry AM; Hale AT; Chambless LB; Weaver KD; Thompson RC; Ihrie RA
J Neurooncol; 2017 Jan; 131(1):125-133. PubMed ID: 27644688
[TBL] [Abstract][Full Text] [Related]
12. Ten-year survival in glioblastoma. A systematic review.
Tykocki T; Eltayeb M
J Clin Neurosci; 2018 Aug; 54():7-13. PubMed ID: 29801989
[TBL] [Abstract][Full Text] [Related]
13. The hedgehog antagonist HHIP as a favorable prognosticator in glioblastoma.
Chang L; Zhang P; Zhao D; Liu H; Wang Q; Li C; Du W; Liu X; Zhang H; Zhang Z; Jiang C
Tumour Biol; 2016 Mar; 37(3):3979-86. PubMed ID: 26482617
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 expression varies significantly among different subtypes of glioblastoma multiforme (GBM) and its low expression or hypermethylation might predict favorable overall survival.
Ma X; Shang F; Zhu W; Lin Q
Expert Rev Neurother; 2017 Sep; 17(9):941-946. PubMed ID: 28685624
[TBL] [Abstract][Full Text] [Related]
15. High Mobility Group Box 1 (HMGB1) Predicts Invasion and Poor Prognosis of Glioblastoma Multiforme via Activating AKT Signaling in an Autocrine Pathway.
Cheng P; Ma Y; Gao Z; Duan L
Med Sci Monit; 2018 Dec; 24():8916-8924. PubMed ID: 30531692
[TBL] [Abstract][Full Text] [Related]
16. Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition.
Gortany NK; Panahi G; Ghafari H; Shekari M; Ghazi-Khansari M
Cancer Chemother Pharmacol; 2021 Jun; 87(6):827-842. PubMed ID: 33688998
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.
Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB
J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma.
Fan S; Meng D; Xu T; Chen Y; Wang J; Li X; Chen H; Lu D; Chen J; Lan Q
Med Oncol; 2013 Mar; 30(1):384. PubMed ID: 23408368
[TBL] [Abstract][Full Text] [Related]
20. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
